9 recruiting, 7 unknown, 4 completed, 2 active not recruiting. 12 Phase 1, 9 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia Eganelisib, Azacitidine, Venetoclax - Leukemia, Myeloid, Leukemia | Phase 1 | Recruiting | Jacqueline Garcia, MD | 48 | 2026-04-13 | 2026-08-26 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia Chemotherapy, HLA-mismatched GPBMC infusion, Allogeneic Stem Cell Transplantation - Relapsed Leukemia, Refractory Leukemia | Phase 1 | Recruiting | Beijing 302 Hospital | 5 | 2025-12-01 | 2025-12-22 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, Dendritic Cell Vaccine - Refractory Leukemia, Relapsed Leukemia | Phase 1 | Withdrawn | Juan C. Ramos, MD | 2023-11-30 | 2023-12-04 | |
| Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia CALGE-VEN- RIC-conditioning - Refractory Leukemia | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 100 | 2023-02-01 | 2025-02-18 |
| Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia BCL2 Inhibitor plus IM2 regimen - T-lymphoblastic Lymphoma, Relapsed Disease | Phase 2 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 30 | 2023-01-10 | 2023-06-28 |
| Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia JK500 cell injection，cyclophosphamide，Fludarabine - Acute Myeloid Leukemia, Childhood, Relapsed Leukemia | Early Phase 1 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2022-09-14 | 2022-11-28 |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Olverembatinib, APG-2575, Dexamethasone - Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 19 | 2022-09-01 | 2026-08-26 |
| Solving Riddles Through Sequencing Next Generation Sequencing - Leukemia, Hematologic Malignancy | Recruiting | Munich Leukemia Laboratory | 100 | 2022-01-19 | 2026-10-09 | |
| Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML venetoclax combining chidamide and azacitidine (VCA) - Leukemia, Myeloid, Acute, Relapsed Adult AML | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2022-01-12 | 2025-09-11 |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia Decitabine, Tegavivint - Recurrent Leukemia, Refractory Leukemia | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 9 | 2021-09-27 | 2026-08-25 |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia | Phase 1 | Recruiting | National University Hospital, Singapore | 20 | 2021-09-08 | 2021-09-14 |
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Modified anti-CD19 CAR T cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia | Phase 1 | Unknown | Liqun Zou | 18 | 2021-03-17 | 2022-09-26 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients Best Practice, Bright White Light Therapy, Survey Administration - Acute Leukemia, Recurrent Leukemia | Not applicable | Completed | Ohio State University Comprehensive Cancer Center | 74 | 2020-09-14 | 2023-04-07 |
| Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy Venetoclax - Chronic Lymphocytic Leukemia, Relapse Leukemia | Active not recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 321 | 2020-07-24 | 2026-06-09 | |
| Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies Next generation functional drug screening, Comprehensive genomic profiling - Advanced Lymphoma, Refractory Lymphoma | Unknown | Medical University of Vienna | 150 | 2020-06-10 | 2024-03-22 |
Showing 20 of 23. Sign in to see all of them.
Leukemia (23) · Leukemia, Myeloid, Acute (10) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Recurrence (4) · Lymphoma (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Hematologic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Neoplasms, Unknown Primary (1) · Rare Diseases (1)
Hematologic Diseases (23) · Hemic and Lymphatic Diseases (23) · Neoplasms (23) · Neoplasms by Histologic Type (23) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Leukemia, Myeloid (9) · Leukemia, Lymphoid (7) · Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Chronic Disease (2) · Leukemia, B-Cell (2)
Azacitidine (3) · venetoclax (3) · Decitabine (2) · Cyclophosphamide (1) · Cytarabine (1) · Dexamethasone (1) · Drug Therapy (1) · Etoposide (1) · Homoharringtonine (1) · IPI-549 (1) · Immunotherapy, Adoptive (1) · Injections (1) · Lisaftoclax (1) · Panobinostat (1) · Practice Guidelines as Topic (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · Beijing 302 Hospital (1) · Chongqing Precision Biotech Co., Ltd (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Jacqueline Garcia, MD (1) · Jennifer R. Brown, MD, PhD (1) · Juan C. Ramos, MD (1) · Liqun Zou (1) · M.D. Anderson Cancer Center (1) · Medical University of Vienna (1) · Memorial Sloan Kettering Cancer Center (1) · Munich Leukemia Laboratory (1) · National University Hospital, Singapore (1) · Novartis Pharmaceuticals (1) · Ohio State University Comprehensive Cancer Center (1)
China (11) · United States (7) · Germany (2) · Italy (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Peru (1) · Singapore (1) · South Korea (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1)
Allen Yeoh, M.D (1) · Bing Xu (1) · Bo Cai, MD (1) · Chun Wang (1) · Dario Campana, M.D, PhD (1) · Han Yue, Ph.D (1) · Jacqueline Garcia, MD (1) · Jennifer Brown, MD, PhD (1) · Jia Wei, M.D (1) · Juan C Ramos, MD (1) · Kuo-Kai Chin, MD (1) · Li Yu, Dr (1) · Shelly Brown, MS, APRN-CNS (1) · Tapan M Kadia (1)
2008 (1)